Back to search results

Rocklatan vs Latanoprost for Glaucoma After Laser Treatment

This study is looking at how well two different eye drop treatments work for adults with mild to moderate open-angle glaucoma (a condition that damages your eye's optic nerve and can lead to vision loss). You might be able to join if you are at least 18 years old, have glaucoma in both eyes, and have already had a laser treatment called Direct Selective Laser Trabeculoplasty (DSLT). Researchers want to see if Rocklatan (a combination of netarsudil and latanoprost) works better than latanoprost alone to lower the pressure inside your eye (intraocular pressure or IOP) after DSLT. The main goal is to measure the change in your eye pressure three months after starting treatment.

Study design
This is a randomized, double-masked study involving 36 participants at one location. This means participants will be randomly assigned to one of two treatment groups, and neither you nor your doctor will know which treatment you are receiving.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal measures eye pressure changes at 3 months after treatment starts.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07465913

Rocklatan vs Latanoprost Post-DSLT

Recruiting
PHASE4Ages 18+InterventionalBasic science
Eye Centers of Southeast Texas
~36 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Rocklatan 0.02%-0.005% Ophthalmic SolutionLatanoprost 0.005% Ophthalmic Solution

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in mean diurnal intraocular pressure (IOP) from baseline
Measured over 3 months post-treatment initiation

Conditions

Glaucoma

Explore related trials

Open Angle GlaucomaPrimary Open Angle Glaucoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Kevin Talbot, MD · PRINCIPAL_INVESTIGATOR · Eye Centers of Southeast Texas

Who to contact

Carol McKee
[email protected]
409-833-0444
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults (≥18 years) with a diagnosis of mild to moderate bilateral primary open-angle glaucoma (POAG) or open-angle glaucoma (OAG).
On 3 topical glaucoma medications at screening, one of which must be a prostaglandin analog.
Post-DSLT and post-washout, baseline intraocular pressure (IOP) 16-36 mmHg in both eyes.
Best-corrected visual acuity (BCVA) ≥20/60 in both eyes.
Ability and willingness to provide informed consent.

Exclusion

Ocular hypertension only (no glaucomatous damage).
Inability or medical ineligibility for washout of ocular hypotensive medications.
Prior selective laser trabeculoplasty (SLT) within 12 months of screening.
History of glaucoma surgery (trabeculectomy, tube shunt, minimally invasive glaucoma surgery \[MIGS\] affecting outflow).
Narrow or closed angles with gonioscopy (Shaffer grading ≤2).
Active ocular infection, uveitis, or severe dry eye.
Corneal pathology interfering with IOP measurement.
Advanced glaucoma (threat to fixation).
Known hypersensitivity to Rocklatan, latanoprost, or study medication components.
Pregnancy or lactation.

What this trial measures

  • Change in mean diurnal intraocular pressure (IOP) from baseline3 months post-treatment initiation